SCHEMBL5115398

SCHEMBL5115398

COc1cccc([N+](=O)[O-])c1NC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
TDP1 Q9NUW8 3/20 0.56
KMT2A Q03164 5/20 0.50
MEN1 O00255 3/20 0.50
TSHR P16473 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 3/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
ALOX12 P18054 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
KCNMA1 Q12791 1/20 0.46
POLB P06746 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115395 1.00 ALDH1A1 (0.56) ALDH1A1TDP1KMT2AMEN1TSHR
SCHEMBL3449044 0.88 ALDH1A1 (0.56) ALDH1A1TDP1KMT2AMEN1TSHR
SCHEMBL4728329 0.83 ALDH1A1 (0.50) ALDH1A1TDP1KMT2AMEN1TSHR
SCHEMBL22499474 0.83 ALDH1A1 (0.50) ALDH1A1TDP1KMT2AMEN1TSHR
SCHEMBL737656 0.83 ALDH1A1 (0.50) ALDH1A1TDP1KMT2AMEN1L3MBTL1
SCHEMBL15767609 0.83 MEN1 (0.54) ALDH1A1TDP1KMT2AMEN1L3MBTL1
SCHEMBL18781780 0.83 ALDH1A1 (0.50) ALDH1A1TDP1KMT2AMEN1L3MBTL1
Oxalic Acid SCHEMBL20984871 0.82 ALDH1A1 (0.53) ALDH1A1TDP1KMT2AMEN1TSHR
SCHEMBL12730443 0.82 ALDH1A1 (0.49) ALDH1A1TDP1KMT2AMEN1L3MBTL1
SCHEMBL14540662 0.82 ALDH1A1 (0.49) ALDH1A1TDP1KMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429583-B2 Betamimetics for the treatment of respiratory complaints BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-30 US disclosed
US-20070249595-A1 Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-25 US disclosed
US-20060063817-A1 New betamimetics for the treatment of respiratory complaints BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063817-A1 New betamimetics for the treatment of respiratory complaints CHRM1, ADRB1, ADRA1B ALDH1A1 1726/4885TDP1 1663/4885KMT2A 3124/4885
US-20070249595-A1 Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof ADRB1, ADRA1B, ADRA2B ALDH1A1 2222/4885TDP1 1622/4885KMT2A 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.